ATE478864T1 - Hydantoinderivate zur behandlung von entzündlichen erkrankungen - Google Patents

Hydantoinderivate zur behandlung von entzündlichen erkrankungen

Info

Publication number: ATE478864T1
Authority: AT; Austria
Prior art keywords: treatment; inflammatory diseases; hydantoine; derivatives; hydantoine derivatives
Prior art date: 2004-07-16

Application number

AT05771446T

Other languages

English (en)

Inventor

Wensheng Yu

Ling Tong

Lei Chen

Joseph Kozlowski

Brian Lavey

Neng-Yang Shih

Vincent Madison

Guowei Zhou

Peter Orth

Zhuyan Guo

Michael Wong

De-Yi Yang

Seong Kim

Bandarpalle Shankar

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-16

Filing date

2005-07-13

Publication date

2010-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35134266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE478864(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-07-13 Application filed by Schering Corp filed Critical Schering Corp

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE478864T1 publication Critical patent/ATE478864T1/de

Links

WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical class O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 title 1
208000027866 inflammatory disease Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Addiction (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Cardiology (AREA)
Toxicology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)

AT05771446T 2004-07-16 2005-07-13 Hydantoinderivate zur behandlung von entzündlichen erkrankungen ATE478864T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58850204P	2004-07-16	2004-07-16
PCT/US2005/024771 WO2006019768A1 (en)	2004-07-16	2005-07-13	Hydantoin derivatives for the treatment of inflammatory disorders

Publications (1)

Publication Number	Publication Date
ATE478864T1 true ATE478864T1 (de)	2010-09-15

Family

ID=35134266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05771446T ATE478864T1 (de)	2004-07-16	2005-07-13	Hydantoinderivate zur behandlung von entzündlichen erkrankungen

Country Status (21)

Country	Link
US (2)	US7482370B2 (de)
EP (1)	EP1778676B1 (de)
JP (1)	JP4943327B2 (de)
KR (1)	KR20070032787A (de)
CN (1)	CN101018782A (de)
AR (1)	AR050169A1 (de)
AT (1)	ATE478864T1 (de)
AU (1)	AU2005275213A1 (de)
BR (1)	BRPI0513433A (de)
CA (1)	CA2573764A1 (de)
DE (1)	DE602005023172D1 (de)
EC (1)	ECSP077163A (de)
ES (1)	ES2349041T3 (de)
IL (1)	IL180736A0 (de)
MX (1)	MX2007000668A (de)
NO (1)	NO20070893L (de)
PE (1)	PE20060561A1 (de)
RU (1)	RU2007105685A (de)
TW (1)	TWI297269B (de)
WO (1)	WO2006019768A1 (de)
ZA (1)	ZA200700384B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7504424B2 (en)	2004-07-16	2009-03-17	Schering Corporation	Compounds for the treatment of inflammatory disorders
DE602005023172D1 (de)	2004-07-16	2010-10-07	Schering Corp	Hydantoinderivate zur behandlung von entzündlichen erkrankungen
US7488745B2 (en)	2004-07-16	2009-02-10	Schering Corporation	Compounds for the treatment of inflammatory disorders
ATE518853T1 (de) *	2005-08-12	2011-08-15	Schering Corp	Verbindungen zur behandlung entzündlicher erkrankungen
AR059037A1 (es) *	2006-01-17	2008-03-12	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
WO2007124181A2 (en) *	2006-04-21	2007-11-01	Amgen Inc.	Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
DE102006037478A1 (de)	2006-08-10	2008-02-14	Merck Patent Gmbh	2-(Heterocyclylbenzyl)-pyridazinonderivate
WO2008027466A1 (en)	2006-08-31	2008-03-06	Schering Corporation	Hydantoin derivatives useful as antibacterial agents
DE102007038957A1 (de)	2007-08-17	2009-02-19	Merck Patent Gmbh	6-Thioxo-pyridazinderivate
US8314131B2 (en)	2007-09-21	2012-11-20	Amgen Inc.	Triazole fused heteroaryl compounds and methods of use thereof
WO2010036638A2 (en) *	2008-09-24	2010-04-01	Schering Corporation	Compounds for the treatment of inflammatory disorders
TW201024303A (en)	2008-09-24	2010-07-01	Schering Corp	Compounds for the treatment of inflammatory disorders
EP2356111A1 (de)	2008-11-10	2011-08-17	Schering Corporation	Verbindungen zur behandlung entzündlicher erkrankungen
US8569336B2 (en)	2008-11-10	2013-10-29	Ling Tong	Compounds for the treatment of inflammatory disorders
HUE042011T2 (hu)	2010-02-11	2019-06-28	Celgene Corp	Arilmetoxi-izoindolin-származékok, azok készítményei és alkalmazási módszereik
ES2592154T3 (es)	2010-07-08	2016-11-28	Kaken Pharmaceutical Co., Ltd.	Derivado de N-hidroxiformamida y medicamento que contiene el mismo
EP2651927A4 (de) *	2010-12-15	2014-06-04	Abbvie Inc	Antivirale verbindungen
WO2012142125A2 (en) *	2011-04-12	2012-10-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
AU2012349288B2 (en) *	2011-12-09	2016-12-01	Kaken Pharmaceutical Co., Ltd.	Pyridone derivative and medicine containing same
WO2013129622A1 (ja)	2012-03-02	2013-09-06	武田薬品工業株式会社	複素環化合物およびその用途
WO2014078802A1 (en)	2012-11-19	2014-05-22	Irm Llc	Compounds and compositions for the treatment of parasitic diseases
JP6211530B2 (ja) *	2012-11-19	2017-10-11	武田薬品工業株式会社	含窒素複素環化合物
CN105189482A (zh)	2013-02-07	2015-12-23	武田药品工业株式会社	作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯
JP6247689B2 (ja)	2013-06-07	2017-12-13	科研製薬株式会社	（＋）−５−（３，４−ジフルオロフェニル）−５−［（３−メチル−２−オキソピリジン−１（２ｈ）−イル）メチル］イミダゾリジン−２，４−ジオンおよびそれを含有する医薬
EP3087069B1 (de)	2013-12-23	2019-01-30	Norgine B.V.	Als ccr9-modulatoren verwendbare verbindungen
US9763992B2 (en)	2014-02-13	2017-09-19	Father Flanagan's Boys' Home	Treatment of noise induced hearing loss
RS63319B1 (sr)	2015-09-02	2022-07-29	Trevena Inc	Jedinjenja koja modulišu delta-opioidni receptor, koja sadrže 6-člani aza-heterociklik, postupci njihove upotrebe i spravljanja
ES2781309T3 (es) *	2016-05-27	2020-09-01	Bristol Myers Squibb Co	Triazolonas y tetrazolonas como inhibidores de ROCK
CN108069942A (zh) *	2016-11-10	2018-05-25	四川大学	苯酞吡唑酮类偶联物、其制备方法和用途
US11702408B2 (en)	2017-02-17	2023-07-18	Trevena, Inc.	5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
KR102662065B1 (ko)	2017-02-17	2024-05-07	트레베나, 인코포레이티드.	7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
JP2021515767A (ja)	2018-03-07	2021-06-24	バイエル・アクチエンゲゼルシヤフト	Ｅｒｋ５阻害剤の同定及び使用
WO2020160074A1 (en)	2019-01-30	2020-08-06	Avista Pharma Solutions, Inc.	Synthetic process and novel intermediates
KR20220100933A (ko)	2019-11-14	2022-07-18	포시 파마슈티컬스 컴퍼니 리미티드	기질 금속단백분해효소(mmp) 억제제 및 이의 사용 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4110536A (en) *	1977-04-18	1978-08-29	Miles Laboratories, Inc.	Derivatives of 5-(indol-3-yl)hydantoin
EP0545478A1 (de) *	1991-12-03	1993-06-09	MERCK SHARP & DOHME LTD.	Heterocyclische Verbindungen als Tachykininantagoniste
US6228869B1 (en)	1996-10-16	2001-05-08	American Cyanamid Company	Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
TR199902124T2 (xx) *	1997-03-03	2000-06-21	Boehringer Ingelheim Pharmaceuticals, Inc.	�ltihapl� hastal�klar�n tedavisinde yararl� k��k molek�ller.
DE60008548T2 (de)	1999-08-18	2004-08-05	Warner-Lambert Co. Llc	Hydroxamsäurederivate als matrix-metalloproteinase-inhibitoren
NZ521245A (en)	2000-03-17	2004-04-30	Bristol Myers Squibb Pharma Co	Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
EE200300439A (et)	2001-03-15	2003-12-15	Astrazeneca Ab	Metalloproteinaasi inhibiitorid
EP1397137B1 (de)	2001-05-25	2009-10-14	Bristol-Myers Squibb Company	Hydantion-derivate als hemmer von matrix-metalloproteinasen
AU2002357312A1 (en)	2001-12-20	2003-07-09	Bristol-Myers Squibb Company	Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
AU2002346729A1 (en)	2001-12-20	2003-07-09	Bristol-Myers Squibb Company	Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
AU2003261319A1 (en)	2002-08-01	2004-02-23	Bristol-Myers Squibb Company	Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
GB0221250D0 (en)	2002-09-13	2002-10-23	Astrazeneca Ab	Compounds
GB0221246D0 (en)	2002-09-13	2002-10-23	Astrazeneca Ab	Compounds
EP1546109A4 (de)	2002-10-04	2005-11-09	Bristol Myers Squibb Co	Hydantoinderivate als inhibitoren von matrix-metallproteinasen und/oder tnf-alpha umsetzendem enzym (tace)
JP4580866B2 (ja)	2002-12-19	2010-11-17	バーテックスファーマシューティカルズインコーポレイテッド	Ｔａｃｅのインヒビター
US7504424B2 (en)	2004-07-16	2009-03-17	Schering Corporation	Compounds for the treatment of inflammatory disorders
US7488745B2 (en)	2004-07-16	2009-02-10	Schering Corporation	Compounds for the treatment of inflammatory disorders
DE602005023172D1 (de)	2004-07-16	2010-10-07	Schering Corp	Hydantoinderivate zur behandlung von entzündlichen erkrankungen
AR059037A1 (es)	2006-01-17	2008-03-12	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
WO2008027466A1 (en)	2006-08-31	2008-03-06	Schering Corporation	Hydantoin derivatives useful as antibacterial agents

2005
- 2005-07-13 DE DE602005023172T patent/DE602005023172D1/de not_active Expired - Lifetime
- 2005-07-13 AR ARP050102901A patent/AR050169A1/es not_active Application Discontinuation
- 2005-07-13 EP EP05771446A patent/EP1778676B1/de not_active Expired - Lifetime
- 2005-07-13 BR BRPI0513433-1A patent/BRPI0513433A/pt not_active IP Right Cessation
- 2005-07-13 ES ES05771446T patent/ES2349041T3/es not_active Expired - Lifetime
- 2005-07-13 MX MX2007000668A patent/MX2007000668A/es active IP Right Grant
- 2005-07-13 CN CNA2005800304595A patent/CN101018782A/zh active Pending
- 2005-07-13 RU RU2007105685/04A patent/RU2007105685A/ru not_active Application Discontinuation
- 2005-07-13 AT AT05771446T patent/ATE478864T1/de not_active IP Right Cessation
- 2005-07-13 JP JP2007521589A patent/JP4943327B2/ja not_active Expired - Fee Related
- 2005-07-13 US US11/180,863 patent/US7482370B2/en not_active Expired - Lifetime
- 2005-07-13 AU AU2005275213A patent/AU2005275213A1/en not_active Abandoned
- 2005-07-13 KR KR1020077001084A patent/KR20070032787A/ko not_active Withdrawn
- 2005-07-13 CA CA002573764A patent/CA2573764A1/en not_active Abandoned
- 2005-07-13 WO PCT/US2005/024771 patent/WO2006019768A1/en not_active Ceased
- 2005-07-14 TW TW094123832A patent/TWI297269B/zh not_active IP Right Cessation
- 2005-07-14 PE PE2005000812A patent/PE20060561A1/es not_active Application Discontinuation
2007
- 2007-01-12 ZA ZA200700384A patent/ZA200700384B/xx unknown
- 2007-01-12 EC EC2007007163A patent/ECSP077163A/es unknown
- 2007-01-16 IL IL180736A patent/IL180736A0/en unknown
- 2007-02-16 NO NO20070893A patent/NO20070893L/no not_active Application Discontinuation
2008
- 2008-12-18 US US12/338,353 patent/US7683085B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
MX2007000668A (es)	2007-03-08
PE20060561A1 (es)	2006-07-13
JP2008506692A (ja)	2008-03-06
US20060205797A1 (en)	2006-09-14
TWI297269B (en)	2008-06-01
AU2005275213A1 (en)	2006-02-23
AR050169A1 (es)	2006-10-04
BRPI0513433A (pt)	2008-05-06
DE602005023172D1 (de)	2010-10-07
NO20070893L (no)	2007-04-13
ECSP077163A (es)	2007-02-28
CN101018782A (zh)	2007-08-15
EP1778676B1 (de)	2010-08-25
KR20070032787A (ko)	2007-03-22
IL180736A0 (en)	2007-06-03
RU2007105685A (ru)	2008-08-27
EP1778676A1 (de)	2007-05-02
WO2006019768A1 (en)	2006-02-23
ES2349041T3 (es)	2010-12-22
CA2573764A1 (en)	2006-02-23
US7683085B2 (en)	2010-03-23
US7482370B2 (en)	2009-01-27
US20090111803A1 (en)	2009-04-30
JP4943327B2 (ja)	2012-05-30
ZA200700384B (en)	2008-09-25
TW200616620A (en)	2006-06-01

Legal Events

Date	Code	Title	Description
2011-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE478864T1 (de)	2010-09-15	Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE434620T1 (de)	2009-07-15	Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005007717D1 (de)	2008-08-07	Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE369333T1 (de)	2007-08-15	Sulfonamidderivate zur behandlung von krankheiten
ATE512663T1 (de)	2011-07-15	Kombination zur behandlung von erkrankungen mit zellproliferation
DE602005005810D1 (de)	2008-05-15	Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE534633T1 (de)	2011-12-15	Indazolderivate zur behandlung von hsp90- induzierten krankheiten
DE602005026984D1 (de)	2011-04-28	Chinolin-derivate zur behandlung von latenter tuberkulose
DE60303238D1 (de)	2006-04-06	Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE375977T1 (de)	2007-11-15	Sulfonamidderivate zur behandlung von krankheiten
ATE440866T1 (de)	2009-09-15	Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
EP1755661A4 (de)	2008-02-20	Verwendung von gelsolin zur behandlung von infektionen
ATE540949T1 (de)	2012-01-15	Substituierte pteridine zur behandlung von entzündlichen erkrankungen
ATE527241T1 (de)	2011-10-15	Pyridiazinonderivate zur behandlung von tumoren
EP2135858A4 (de)	2012-02-08	Zusammensetzung zur behandlung von infektionserkrankungen
ATE476414T1 (de)	2010-08-15	Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE429218T1 (de)	2009-05-15	Pinolensäure zur behandlung von übergewicht
ATE537150T1 (de)	2011-12-15	Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate
ATE443704T1 (de)	2009-10-15	Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1965827A4 (de)	2009-12-23	Behandlung von entmyelinisierenden erkrankungen
ATE525355T1 (de)	2011-10-15	1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
EP1924269A4 (de)	2009-12-16	Vegetationswasser-zusammensetzung zur behandlung von entzündlichen hautkrankheiten
DE602007009877D1 (de)	2010-11-25	Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
EP1773779A4 (de)	2009-09-23	Nicotinrezeptoragonisten zur behandlung entzündlicher krankheiten
DE602005016141D1 (de)	2009-10-01	S-mirtazapin zur behandlung von hitzewallungen